Navigation Links
Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
Date:7/31/2013

CAMBRIDGE, Mass., July 31, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Joseph Bolen, Ph.D., joined Moderna as its president of research and development (R&D).

Dr. Bolen, the chief scientific officer and global head of oncology research at Millennium: The Takeda Oncology Company has served in senior leadership positions at Millennium since 1999. As the Millennium CSO and global head of research, Dr. Bolen has a proven track record of leading a large and multi-faceted international R&D organization while fostering a culture of scientific innovation within a global commercial-stage company. He has more than 30 years of industry and research experience and has been at the forefront of cancer and immunology research since starting his career as a scientist at the National Institutes of Health (NIH).

"Messenger RNA therapeutics™ promises to vastly expand the number of diseases we can treat and usher in an entirely new era of drug discovery and development," said Stephane Bancel, president and founding CEO of Moderna. "To advance our internal programs in genetic rare diseases and oncology and support partners in many additional therapeutic areas, we are building an R&D organization that is second to none. Joe's deep scientific knowledge and strong vision will help us to create a culture and a structure that can move rapidly to turn scientific innovation into therapies that make a true difference for patients. I am very happy and honored to partner with such an accomplished and thoughtful scientific leader and drug hunter as Joe to build a very special company for patients and our team."

Dr. Bolen will oversee all aspects of R&D at Moderna, including discovery research, preclinical and clinical development, and clinical operations. His team will drive the discovery and development of compounds to support Moderna's existing and future research partnerships, as well as its internal efforts in rare diseases and oncology.

"The global scientific community is just beginning to understand the significant promise of Moderna's mRNA technology to advance science and improve human health. I am tremendously excited about expanding our knowledge of this new scientific field and pioneering the clinical application of this modality, which holds such great potential to treat a vast array of human diseases," Dr. Bolen said. "As someone who has dedicated his career to the discovery and development of innovative new medicines for people with cancer, I believe the therapeutic potential of Moderna's novel technology in oncology is particularly compelling. I am excited to work with the dedicated scientists and physicians at Moderna to build a respected R&D organization that is both scalable and flexible, with a clear focus on bringing better medicines to people with life-threatening illnesses."  

Prior to joining Millennium in 1999, Dr. Bolen held senior R&D positions at Hoechst Marion Roussel, Schering-Plough, and Bristol-Myers Squibb. He served as a member of the graduate faculty in the Department of Molecular Biology at Princeton University and spent 10 years at NIH where he made significant contributions to the discovery of a class of proteins known as tyrosine kinase oncogenes as key regulators of the immune system. He has published more than 200 peer-reviewed scientific articles and book chapters and presented hundreds of lectures and seminars at leading universities and national and international scientific meetings. Dr. Bolen graduated from the University of Nebraska with a B.S. degree in Microbiology & Chemistry and a Ph.D. in Immunology and conducted his postdoctoral training in Molecular Virology at the Kansas State University Cancer Center.

About Moderna Therapeutics
Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including 144 patent applications with 6,910 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Massachusetts. Visit www.modernatx.com to learn more.

For information contact:
Dan Quinn
Feinstein Kean Healthcare
617-761-6732
dan.quinn@fkhealth.com

 


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Biotechnology (BSMA) Conference For Supply Chain Professionals Returns To Foster City, October 8-9, 2013
2. Plant Biotechnology Companies Begin New Conversation about GMOs and How our Food is Grown
3. Nobel Laureate Dr. Oliver Smithies to Deliver Plenary Session at ISPE Biotechnology Symposium
4. Biotech Investment Group Launches Formex, LLC
5. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
6. TriMix for Travel Now Available at KRS Global Biotechnology
7. Chief Medical Officer Summit for Biotechs Goes West
8. PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining centers ... The result of a collaboration among several companies with expertise in toolholding, cutting ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):